Truist Financial Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating
Amneal Pharmaceuticals Is Maintained at Overweight by Piper Sandler
Amneal Pharmaceuticals Analyst Ratings
Piper Sandler Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $11
Barclays Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $10
Barclays Reaffirms Their Buy Rating on Amneal Pharmaceuticals (AMRX)
Barclays Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $10
Amneal Pharmaceuticals (AMRX) Receives a Buy From Barclays
Amneal Pharmaceuticals Analyst Ratings
Truist Financial Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $12
Amneal Pharmaceuticals (AMRX) Gets a Buy From Truist Financial
J.P. Morgan Maintains Amneal Pharmaceuticals(AMRX.US) With Hold Rating, Maintains Target Price $9
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (AMRX), Aura Biosciences Inc (AURA) and Terns Pharmaceuticals (TERN)
Organon Downgraded, Amneal Upgraded as J.P. Morgan Reviews Specialty Pharma
Amneal Pharmaceuticals Price Target Announced at $9.00/Share by JP Morgan
Amneal Pharmaceuticals Analyst Ratings
J.P. Morgan Initiates Amneal Pharmaceuticals(AMRX.US) With Hold Rating, Announces Target Price $9
Amneal Pharmaceuticals Analyst Ratings
Barclays Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $10
Amneal Pharmaceuticals (AMRX) Gets a Buy From Barclays